326 related articles for article (PubMed ID: 34575160)
1. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.
Lee J; Han JW; Sung PS; Lee SK; Yang H; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Oh JS; Chun HJ; Bae SH; Choi JY; Yoon SK
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575160
[TBL] [Abstract][Full Text] [Related]
2. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.
Yuan W; Yue W; Wen H; Wang X; Wang Q
Eur Surg Res; 2023; 64(2):268-277. PubMed ID: 36812900
[TBL] [Abstract][Full Text] [Related]
3. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
4. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
Lin LW; Ke K; Yan LY; Chen R; Huang JY
Front Oncol; 2023; 13():1178428. PubMed ID: 37207144
[TBL] [Abstract][Full Text] [Related]
7. Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.
Chen S; Shi F; Wu Z; Wang L; Cai H; Ma P; Zhou Y; Mai Q; Wang F; Tang S; Zhuang W; Lai J; Chen X; Chen H; Guo W
J Hepatocell Carcinoma; 2023; 10():1209-1222. PubMed ID: 37533600
[TBL] [Abstract][Full Text] [Related]
8. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.
Li Y; Liu W; Chen J; Chen Y; Guo J; Pang H; Zhang W; An C; Li C
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38196277
[TBL] [Abstract][Full Text] [Related]
9. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
[TBL] [Abstract][Full Text] [Related]
11. Advanced hepatocellular carcinoma with major portal vein invasion: Therapeutic outcomes of hepatic arterial infusion chemotherapy vs concurrent radiotherapy.
Chiang CL; Liang HL; Chang KC; Tsai WL; Yu HC; Lin KH; Li MF
J Chin Med Assoc; 2024 Feb; 87(2):171-178. PubMed ID: 38099672
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma.
Long F; Chen S; Li R; Lin Y; Han J; Guo J; Chen Y; Li C; Song P
Med Oncol; 2023 Apr; 40(5):147. PubMed ID: 37043113
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice.
Lin LW; Ke K; Chen R; Yang WZ; Huang N; Wu ZZ
Front Immunol; 2023; 14():1286771. PubMed ID: 38288113
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
[TBL] [Abstract][Full Text] [Related]
17. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
Lai Z; Huang Y; Wen D; Lin X; Kan A; Li Q; Wei W; Chen M; Xu L; He M; Shi M
BMC Med; 2022 Oct; 20(1):415. PubMed ID: 36310160
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
Liu Y; Qiao Y; Zhou M; Guo J; Lin Y; Li W; An C; Li C
Cancer Med; 2023 Mar; 12(5):5436-5449. PubMed ID: 36254376
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
[TBL] [Abstract][Full Text] [Related]
20. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
